Pfizer Inc. (NYSE:PFE) Is Foundation Resource Management Inc.'s 9th Largest Position
Pfizer Inc. (NYSE:PFE) Is Foundation Resource Management Inc.'s 9th Largest Position
Foundation Resource Management Inc. decreased its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 0.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 394,929 shares of the biopharmaceutical company's stock after selling 1,337 shares during the period. Pfizer accounts for 3.7% of Foundation Resource Management Inc.'s investment portfolio, making the stock its 9th biggest position. Foundation Resource Management Inc.'s holdings in Pfizer were worth $20,706,000 as of its most recent filing with the SEC.
據基金會資源管理公司提交給美國證券交易委員會的最新Form 13F文件顯示，該公司在第二季度減持了輝瑞的股份0.3%。該機構投資者在此期間出售了1,337股後，持有這家生物製藥公司的394,929股股票。輝瑞佔Foundation Resources Management Inc.投資組合的3.7%，使輝瑞成為輝瑞第9大持倉。截至基金會資源管理公司最近提交給美國證券交易委員會的文件，輝瑞所持輝瑞股份價值20，70.6萬美元。
Several other hedge funds also recently bought and sold shares of PFE. Piscataqua Savings Bank raised its holdings in Pfizer by 0.8% during the second quarter. Piscataqua Savings Bank now owns 25,820 shares of the biopharmaceutical company's stock valued at $1,354,000 after buying an additional 197 shares in the last quarter. Birinyi Associates Inc. raised its holdings in Pfizer by 3.4% during the first quarter. Birinyi Associates Inc. now owns 6,000 shares of the biopharmaceutical company's stock valued at $311,000 after buying an additional 200 shares in the last quarter. Curbstone Financial Management Corp raised its holdings in Pfizer by 0.3% during the first quarter. Curbstone Financial Management Corp now owns 65,901 shares of the biopharmaceutical company's stock valued at $3,412,000 after buying an additional 200 shares in the last quarter. Douglass Winthrop Advisors LLC raised its holdings in Pfizer by 0.3% during the first quarter. Douglass Winthrop Advisors LLC now owns 57,804 shares of the biopharmaceutical company's stock valued at $2,993,000 after buying an additional 200 shares in the last quarter. Finally, LifeSteps Financial Inc. raised its holdings in Pfizer by 2.5% during the second quarter. LifeSteps Financial Inc. now owns 8,179 shares of the biopharmaceutical company's stock valued at $429,000 after buying an additional 201 shares in the last quarter. Hedge funds and other institutional investors own 67.90% of the company's stock.
其他幾家對衝基金最近也買賣了PFE的股票。Piscataqua Savings Bank在第二季度增持了0.8%的輝瑞股份。Piscataqua Savings Bank現在持有這家生物製藥公司25,820股股票，價值1,354,000美元，上個季度又購買了197股。Birinyi Associates Inc.在第一季度將其在輝瑞的持股增加了3.4%。Birinyi Associates Inc.現在持有這家生物製藥公司6,000股股票，價值311,000美元，上個季度又購買了200股。第一季度，Curbstone Financial Management Corp將其在輝瑞的持股增加了0.3%。Curbstone Financial Management Corp目前持有這家生物製藥公司65,901股股票，價值3,412,000美元，此前該公司在上個季度又購買了200股。道格拉斯·温斯羅普顧問公司第一季度將其在輝瑞的持有量增加了0.3%。DouGlass Winthrop Advisors LLC現在擁有這家生物製藥公司57,804股股票，價值2993,000美元，上個季度又購買了200股。最後，LifeSteps Financial Inc.在第二季度增持了2.5%的輝瑞股份。LifeSteps Financial Inc.現在持有這家生物製藥公司8,179股股票，價值42.9萬美元，上個季度又購買了201股。對衝基金和其他機構投資者持有該公司67.90%的股票。
Analysts Set New Price Targets
分析師設定新的價格目標
PFE has been the topic of several recent research reports. SVB Leerink cut their target price on Pfizer from $55.00 to $53.00 and set a "market perform" rating on the stock in a report on Friday, July 29th. Morgan Stanley lowered their price target on Pfizer from $52.00 to $49.00 and set an "equal weight" rating on the stock in a research report on Friday, July 8th. UBS Group set a $59.00 price target on Pfizer in a research report on Thursday, September 1st. The Goldman Sachs Group set a $50.00 price target on Pfizer in a research report on Thursday, September 1st. Finally, Barclays set a $50.00 price target on Pfizer in a research report on Thursday, September 1st. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.00.
PFE一直是最近幾份研究報告的主題。SVB Leerink在7月29日週五的一份報告中將輝瑞的目標價從55.00美元下調至53.00美元，並對該股設定了“市場表現”評級。摩根士丹利在7月8日週五的一份研究報告中將他們對輝瑞的目標價從52.00美元下調至49.00美元，並對該股設定了“同等權重”的評級。瑞銀集團在9月1日週四的一份研究報告中為輝瑞設定了59.00美元的目標價。9月1日星期四，高盛在一份研究報告中為輝瑞設定了50美元的目標價。最後，巴克萊在9月1日週四的一份研究報告中為輝瑞設定了50.00美元的目標價。9名投資分析師對該股的評級為持有，10名分析師給出了買入評級，一名分析師給出了該公司股票的強力買入評級。根據MarketBeat.com的數據，該公司目前的共識評級為“適度買入”，共識目標價為57.00美元。
Pfizer Stock Down 1.1 %
輝瑞股價下跌1.1%
Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.95 by $0.09. The firm had revenue of $27.74 billion during the quarter, compared to analysts' expectations of $26.20 billion. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The company's revenue for the quarter was up 46.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.07 earnings per share. On average, research analysts anticipate that Pfizer Inc. will post 6.54 earnings per share for the current year.
輝瑞(NYSE：PFE-GET Rating)上一次公佈季度收益是在7月28日星期四。這家生物製藥公司公佈本季度每股收益為2.04美元，比分析師普遍預期的1.95美元高出0.09美元。該公司本季度營收為277.4億美元，高於分析師預期的262億美元。輝瑞的淨利潤率為28.92%，股本回報率為43.18%。該公司本季度的收入與去年同期相比增長了46.8%。去年同期，該公司每股收益為1.07美元。研究分析師平均預計，輝瑞公司本年度每股收益將達到6.54美元。
Pfizer Announces Dividend
輝瑞宣佈分紅
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Shareholders of record on Friday, November 4th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 3.63%. The ex-dividend date of this dividend is Thursday, November 3rd. Pfizer's dividend payout ratio is 31.31%.
該公司最近還宣佈了季度股息，將於12月5日(星期一)支付。11月4日(星期五)登記在冊的股東將獲得每股0.40美元的股息。這意味着年化股息為1.60美元，收益率為3.63%。本次股息除息日期為11月3日(星期四)。輝瑞的派息比率為31.31%。
About Pfizer
關於輝瑞公司
(Get Rating)
(獲取評級)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
輝瑞在全球發現、開發、製造、營銷、分銷和銷售生物製藥產品。該公司在不同的治療領域提供藥物和疫苗，包括Premarin系列和Eiquis品牌的心血管代謝和婦女健康；Ibrance、Xtandi、Sutent、Inlyta、Retacritt、Lorbrena和Braftovi品牌的生物製品、小分子、免疫療法和生物仿製藥；舒必樂、Medrol、Zavicefta、Zithromax、Vfend、Panzyga和Paxlovid品牌的無菌注射和抗感染藥物以及口服新冠肺炎治療。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 免費獲取StockNews.com關於輝瑞的研究報告
- 華爾街對Datadog的熱情會帶來巨大的收益嗎？
- MarketBeat：回顧一週9/19-9/23
- 為什麼特斯拉的股票保持彈性？
- 好市多盈利後價格疲軟是買入的好時機嗎？
- 小盤股的裁員是樓市的晴雨表嗎？
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
接受輝瑞日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對輝瑞及相關公司評級的每日簡明摘要。
譯文內容由第三人軟體翻譯。